MEDP (Medpace Holdings) Current Accrued Expense: $372 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEDP Medpace Holdings Inc MEDP
97 GF Score
Price $591.20
GF Value $534.93
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Medpace Holdings Current Accrued Expense?

Medpace Holdings MEDP -0.36% 97 Current Accrued Expense is $372 Mil as of Jun. 2026. GuruFocus rates MEDP with a GF Score™ of 97/100 and a GF Value™ of $534.93 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Medpace Holdings's Current Accrued Expense for the quarter that ended in Jun. 2026 was $372 Mil.

Medpace Holdings's quarterly Current Accrued Expense increased from Dec. 2025 ($328 Mil) to Mar. 2026 ($344 Mil) and increased from Mar. 2026 ($344 Mil) to Jun. 2026 ($372 Mil).

Medpace Holdings's annual Current Accrued Expense increased from Dec. 2023 ($217 Mil) to Dec. 2024 ($223 Mil) and increased from Dec. 2024 ($223 Mil) to Dec. 2025 ($328 Mil).

Medpace Holdings Current Accrued Expense Related Terms

Medpace Holdings Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Medpace Holdings's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medpace Holdings Current Accrued Expense Chart

Medpace Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 101.44 138.93 217.14 222.88 328.24

Medpace Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 255.27 285.67 328.24 344.46 371.65
MEDP
97GF Score
Medpace Holdings Inc MEDP
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medpace Holdings Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $372 Mil mean?
Medpace Holdings (MEDP) has a Current Accrued Expense of $372 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Medpace Holdings and its competitors.
Is Medpace Holdings' Current Accrued Expense too high?
Medpace Holdings' current Current Accrued Expense is $372 Mil. Overall, Medpace Holdings has a GF Score™ of 97/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' Current Accrued Expense compare to RVTY and CRL?
Medpace Holdings' Current Accrued Expense of $372 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Medical Diagnostics & Research company?
A good Current Accrued Expense depends on the Medical Diagnostics & Research industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Medpace Holdings and its competitors. Medpace Holdings's current Current Accrued Expense is $372 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medpace Holdings (MEDP) is currently considered Modestly Overvalued. The stock's GF Value™ is $534.93, compared to a current price of $591.20 — trading 10.5% above its estimated fair value. The current Current Accrued Expense is $372 Mil. Medpace Holdings' overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Medpace Holdings (MEDP), the current Current Accrued Expense is $372 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medpace Holdings (MEDP) Overvalued in 2026?

Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued. The current stock price of $591.20 is trading 10.5% above its estimated GF Value™ of $534.93. GuruFocus considers Medpace Holdings to be Modestly Overvalued.

Key valuation signals for MEDP:

  • Current Accrued Expense: $372 Mil
  • GF Value™: $534.93 vs. price of $591.20 (10.5% above fair value)
  • GF Score™: 97/100 with 2 warning signs

No single metric tells the full story. See the MEDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medpace Holdings Business Description

Other Exchanges MEDP:Mexico01P:Germany
Address 5375 Medpace Way, Cincinnati, OH, USA, 45227
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
97GF Score

Get the complete analysis for MEDP

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$591.20
Price
$534.93
GF Value